Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 4
1990 2
1991 3
1992 2
1993 2
1994 2
1995 4
1996 7
1997 3
1998 4
1999 5
2000 5
2001 8
2002 5
2003 9
2004 13
2005 9
2006 14
2007 8
2008 7
2009 11
2010 8
2011 8
2012 13
2013 12
2014 11
2015 17
2016 24
2017 13
2018 18
2019 11
2020 16
2021 11
2022 12
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Riaz N, et al. Among authors: gajewski tf. Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12. Cell. 2017. PMID: 29033130 Free PMC article.
CXCL9 and CXCL10 bring the heat to tumors.
Reschke R, Gajewski TF. Reschke R, et al. Among authors: gajewski tf. Sci Immunol. 2022 Jul 22;7(73):eabq6509. doi: 10.1126/sciimmunol.abq6509. Epub 2022 Jul 22. Sci Immunol. 2022. PMID: 35867802 Review.
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. Deng L, et al. Among authors: gajewski tf. Immunity. 2014 Nov 20;41(5):843-52. doi: 10.1016/j.immuni.2014.10.019. Epub 2014 Nov 6. Immunity. 2014. PMID: 25517616 Free PMC article.
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Olson DJ, et al. Among authors: gajewski tf. J Clin Oncol. 2021 Aug 20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. Epub 2021 May 4. J Clin Oncol. 2021. PMID: 33945288 Free PMC article. Clinical Trial.
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Chesney JA, et al. Among authors: gajewski tf. J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23. J Clin Oncol. 2023. PMID: 35998300 Free PMC article. Clinical Trial.
287 results